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Background: Botulinum toxin type A is a valid and safe treatment for focal spasticity, with documented
effects on both sympathetic and parasympathetic systems. Heart rate variability can provide detailed
information about the control of the autonomic nervous system on cardiovascular activities. Previous
studies in literature showed no significant changes in Heart Rate Variability with doses >600 U of
incobotulinumtoxinA in chronic post stroke spastic patients; however, at present time, these results have
not been confirmed with doses >600 U of onabotulinumtoxinA.
Aim: To evaluate changes in Heart Rate Variability induced by high doses (>600 U) of incobotuli-
numtoxinA or onabotulinumtoxinA in spastic stroke patients over a 1-year period.
Design: single blind randomized controlled crossover study design.
Setting: Rehabilitation Unit of the University Hospital in Novara.
Population: 10 stroke survivors with spastic hemiplegia (Modified Ashworth Scale  2) were recruited
and randomly divided in two groups (A and B).
Methods: In the first part of the study, patients in Group A were injected with incobotulinumtoxinA
while patients in Group B with onabotulinumtoxinA; after 6 months, a crossover intervention was
performed. All patients were blinded to Botulinum toxin type A type, and performed an ECG registration
in the 24 h before injection (t0) and 10 days after treatment (t1), both in the first and in the second part
of the study. Functional status was evaluated with Barthel Index, Motricity Index and Functional
Ambulation Category scores.
Results: Heart Rate Variability analysis showed no significant changes after each Botulinum toxin type A
injection in both groups at any evaluation time. Moreover, no statistically significant differences were
found regarding each variable between the two groups.
Conclusions: Our data show that high doses (>600 U) of incobotulinumtoxinA and onabotulinumtoxinA
do not influence the cardiovascular activity of the autonomic nervous system in chronic hemiplegic
spastic stroke survivors.
© 2017 Elsevier Ltd. All rights reserved.ve Medicine, Department of
ogadro”, Viale Piazza D'Armi
M. Invernizzi).1. Introduction
Botulinum toxin type A (BoNT-A) has been considered as an
effective and safe treatment for focal spasticity in stroke survivors
A. Baricich et al. / Toxicon 138 (2017) 145e150146(Baker and Pereira, 2013).
BoNT-A can directly modify the heart function acting on the
sympathetic (through the preganglionic sympathetic innervation)
and parasympathetic systems (through the vagal nerve) (Girlanda
et al., 1992), and at present time there is no general consensus on
the maximum dose of BoNT-A in terms of safety and clinical
interchangeability among the three commercially approved prod-
ucts (abobotulinumtoxinA, onabotulinumtoxinA, incobotuli-
numtoxinA). In clinical practice the maximum dose admitted per
session is up to 400e600 units (U) both for onabotulinumtoxinA
(Francisco, 2004; Brin, 1997) and for incobotulinumtoxinA (Wissel
and Kempf, 2012). However, two recent open-label studies sug-
gested the safety of doses up to 840 U of incobotulinumtoxinA
(Santamato et al., 2013) and of doses up to 800 U of onabotuli-
numtoxinA (Baricich et al., 2015) for spasticity treatment in stroke
survivors.
Heart Rate Variability (HRV) is a simple and non-invasive elec-
trocardiographic derived measure useful to monitor the control of
the autonomic nervous system (ANS) on cardiovascular activities
including vagal and sympathetic ones (Task Force, 1996; Akselrod
et al., 1981). In consideration of its accessibility and low invasive-
ness, HRV measurement represents a functional indicator of the
ANS activity, being a valid method to study the potential impact of
high doses of BoNT-A on the autonomic drive directed to the heart
in stroke survivors.
Recently no relevant changes have been showed in the auto-
nomic heart drive measured by HRV with doses >600 U of inco-
botulinumtoxinA in patients with chronic spasticity (Invernizzi
et al., 2015). However, at present time, instrumental data about
safety of high doses (>600 U) of onabotulinumtoxinA in chronic
stroke survivors are lacking. To our knowledge, only Dressler
evaluated in a crossover study the safety of high doses of incobo-
tulinumtoxinA (mean dose 450.5 ± 177.1 U) in patients affected by
spasticity and previously treatedwith onabotulinumtoxinA at same
doses, showing no differences between the two products in terms
of efficacy and adverse events occurrence, evaluated clinically, but
without any functional or instrumental indicator (Dressler, 2009).
Similarly, Baricich et al. evaluated the efficacy and safety in terms of
adverse events of high doses of onabotulinumtoxinA (up to 800 U
with a mean of 676.9 ± 86.3 U) in stroke survivors through a clinical
evaluation (Baricich et al., 2015). Lastly, Lee et al. compared the
efficacy and safety of incobotulinumtoxinA with onabotuli-
numtoxinA in treating periocular rhytides and masseteric hyper-
trophy, showing no differences between the two molecules (Lee
et al., 2014); however, the maximum dose used was far lower
compared to those normally prescribed to treat post stroke
spasticity.
In light of these considerations, the aim of this study was to
evaluate changes in HRV induced by high doses (>600 U) of inco-
botulinumtoxinA or onabotulinumtoxinA in spastic stroke patients
over a 1-year period using a crossover study design. Moreover, we
assessed the treatment safety by monitoring adverse events
occurrence.
2. Materials and methods
2.1. Patients
This work was a randomized, single blind, controlled crossover
study. A total of 10 stroke survivors with spastic hemiplegia were
consecutively enrolled at the Rehabilitation Unit of the University
Hospital in Novara from September 2014 to January 2015. The in-
clusion criteria were: I) focal spasticity graded 2 on Modified
Ashworth Scale (Bohannon and Smith, 1987) at upper and lower
limb muscles, requiring at least 600 incobotulinumtoxinA units; II)hemiplegia after ischaemic or haemorrhagic stroke documented by
CT scan and/or available case history; III) age > 18 years. Exclusion
criteria were: I) heart failure with NYHA 3; II) previous diagnosis
of cardiac arrhythmia; III) concomitant use of beta-blockers; IV)
pace-maker implant; V) presence of fixed contractures at BoNT-A
target muscles.
2.2. Study design
After the enrollment, patients were allocated to one of the two
treatment arms by the use of a randomization scheme generated by
software. Patients were then divided into two groups (A and B) and
entered the first part of the study. In this first part of the study,
patients in group A were injected with incobotulinumtoxinA (NT
201; Xeomin®, Merz Pharmaceuticals GmbH, Frankfurt, Germany)
with a dilution of 100 units/2 mL of 0.9% sterile saline, while group
B patients were injected with onabotulinumtoxinA (Botox® Aller-
gan, Irvine, CA, USA), 100 MU in 2 ml of 0.9% sterile saline. Patients
in both groups were blinded to BoNT-A treatment type and
received doses below 12 units/Kg.
After 6 months, the second part of the study started, and each
group received the crossover intervention: group A patients were
treatedwith onabotulinumtoxinA (Botox® Allergan, Irvine, CA, USA,
100 MU in 2 ml 0.9%NaCl/H2O), whereas group B patients were
treated with incobotulinumtoxinA (NT 201; Xeomin®, Merz Phar-
maceuticals GmbH, Frankfurt, Germany with a dilution of 100
units/2 mL of 0.9% sterile saline). The same target muscles and
doses of the first part of the study were maintained. Study design is
described in Fig. 1.
Patients were blinded to BoNT-A treatment type during the
whole study period. Each patient signed an informed consent to the
treatment and the evaluations of this study. The local committee of
our Hospital approved our protocol, which was conducted ac-
cording to the principles of the Declaration of Helsinki.
2.3. Assessment
All patients in both groups performed a total of four ECG reg-
istrations of 30 min each. In the first part of the study, patients
performed the ECG registration in the 24 h before BoNT-A injection
(baseline, t0) and 10 days after the treatment (t1); similarly, in the
second, crossover, part of the study, they performed the ECG
registration 24 h before the new BoNT-A injection and 10 days after
the treatment. Each ECG recording was performed as described
elsewhere (Invernizzi et al., 2015).
Treatment safety was assessed by monitoring adverse events
occurrence of any degree.
Lastly, the following functional measures were recorded at
baseline: Barthel Index (Shah et al., 1989), Motricity Index (MI) for
upper and lower limbs (Collin and Wade, 1990), Functional ambu-
lation category (FAC) (Collen et al., 1990).
Data obtained from analogic ECG were processed with an A/D
converter (micro 1401 CED© Cambridge Electronic Design, Cam-
bridge, UK) and recorded on a PC by means of a data acquisition
system (Spike2 v.5, CED) with a sampling rate of 3000 Hz. Guide-
lines were followed for time recordings, sampling rate and HRV
analysis of electrocardiograms (Task Force, 1996). Artifacts and
noise regions were removed, and, in case of premature beats, they
have been manually corrected. Only the recordings that contained
<1% of premature beats were considered.
ECG's have been analysed by means of software called “Kubios
HRV analysis”, originally created by Niskanen et al. (2004). In this
study we considered both linear and non-linear HRV indexes
(Buccelletti et al., 2012). A detailed description of all linear and non-
linear HRV indexes used in this study can be found in the
Fig. 1. Study design.
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Statistical analysis was performed using the GraphPad 6 pack-
age, version 6.0 (GraphPad Software, Inc., San Diego, CA, USA). The
patients were randomly assigned to one of the treatment arms
using a randomization scheme generated by software with a 1:1
allocation and without blocks. Due to the small sample size, we
supposed a non-gaussian distribution of variables.
Differences between each variable in each group have been
evaluated with Friedman's analysis of variance (ANOVA) and Dunn
post hoc comparison was used to identify significant differences
between mean values. Differences between single variables in
different groups were evaluated with the ManneWhitney Ue test.
A type I error (alpha) level of 0.05 was chosen.3. Results
Demographic data of the enrolled patients, dose/kg and mean
overall doses of onabotulinumtoxinA and incobotulinumtoxinA
utilised are resumed in Table 1. As shown in Tables 2 and 3, none of
the variables considered for time, frequency and non-linear do-
mains showed any statistically significant changes after each BoNT-
A injection in both Groups A and B at any evaluation time. More-
over, no statistically significant differences were found regarding
each variable considered between the two groups. Lastly, one pa-
tient in each group experienced mild, self-limiting adverse events
after the treatment (pain at the injection site). In each case, adverse
events were related to the injection procedure and spontaneously
resolved without any intervention 15 min after treatment.4. Discussion
The results of this study show that high doses (>600 U) of
incobotulinumtoxinA and onabotulinumtoxinA do not influence
the autonomic drive directed to the heart in chronic hemiplegic
spastic stroke survivors. These results are also confirmed if the two
BoNT-A formulations are interchanged in a crossover design sug-
gesting the potential absence of cumulative effects. Moreover, both
the treatment with incobotulinumtoxinA and the treatment with
onabotulinumtoxinA showed only one mild self-limiting adverse
event in each group, related to the injective procedure and spon-
taneously resolved.
The results obtained in this study not only confirm the safety of
incobotulinumtoxinA from a cardiovascular point of view, but also,
for the first time, produce data about the autonomic heart modi-
fications in stroke survivors with spasticity treated with high doses
(>600 U) of onabotulinumtoxinA. In 2009, Dressler in a crossover
prospective study converted patients previously treated with
onabotulinumtoxinA to incobotulinumtoxinA and repeatedly
injected them for 3 years, monitoring clinical efficacy and adverse
events occurrence. The author did not find any difference in the
efficacy, treatment duration and adverse events occurrence after
changing the two drug formulations, suggesting a clinical equiva-
lence of the two BoNT-A formulations (Dressler, 2009). Our results
are somehow comparable with those obtained by Dressler,
considering also the fact that all outcome measures related to
safety in that study were obtained with an anamnestic evaluation
only, without any instrumental objective measure. More recently,
Mehnert et al. showed similar results observing onabotuli-
numtoxinA effects on cardiac function after intradetrusor injection,
showing no HRV modifications after treatment (Mehnert et al.,
2016). The absence of a relevant effect on the autonomic drive
Table 1
Patients' demographical and clinical characteristics. Data are presented as mean ± standard deviation (SD), median and IQR.
Total Group A Group B
Patients (n) 10 5 5







Male (n) 7 3 4
Female (n) 3 2 1







Ischemic (n) 5 3 2
Hemorragic (n) 5 2 3

















































Results of linear variables of the two groups in the first part of the study and after the crossover procedure, before and after BoNT-A treatment. Mean RR: mean value of RR
intervals; Mean HR: mean value of heart rate; RMSSD: root mean square of successive differences; NN50: number of successive intervals differing more than 50 ms; pNN50:
relative amount of successive intervals differing more than 50 ms; RR tri index: HRV triangular index; TINN: baseline width of the RR histogram; AR LF: autoregressive
modeling based method Low Frequency; AR HF: autoregressive modeling based method High Frequency; AR LF/HF: autoregressive modeling based method Low/High fre-


















Mean RR (ms) 807 (79.75) 832 (160.9) 865 (101.5) 885 (108.7) 826 (84.12) 813 (73.2) 859 (88.2) 863 (75.44)
Mean HR (1/min) 75.11 (7.83) 74.18 (13.16) 70.18 (8.15) 69.02 (9.6) 77.3 (6.4) 73.9 (7.4) 72.8 (6.9) 74.5 (8.12)
RMSSD (ms) 29.88 (8.38) 41.15 (18.78) 26.05 (8.78) 41.5 (35.37) 31.45 (7.25) 36.15 (8.42) 33.6 (9.42) 39.7 (7.56)
NN50 (count) 24.5 (14.55) 40.75 (11.59) 22.25 (18.14) 46.1 (24.5) 21.6 (15.29) 32.35 (11.75) 19.8 (13.26) 39.1 (18.01)
pNN50 (%) 3.75 (2.121) 6.03 (2.51) 3.43 (3.3) 6.63 (3.95) 4.8 (2.2) 5.66 (2.48) 4.34 (2.33) 6.63 (2.87)
RR tri index 7.1 (2.66) 7.27 (2.38) 7.16 (0.92) 9.96 (1.39) 8.3 (2.94) 7.87 (2.56) 7.69 (3.47) 6.85 (2.94)
TINN (ms) 241.3 (62.23) 233.8 (38.16) 192.5 (92.42) 242.5 (140.3) 211.6 (58.22) 219.6 (60.73) 187.44 (61.3) 196.2 (54.89)
AR LF (n.u.) 56.4 (29.85) 42.6 (23.87) 56.03 (18.83) 55.35 (19.22) 51.6 (23.13) 50.62 (19.84) 53.4 (20.02) 55.35 (22.66)
AR HF (n.u.) 44.13 (19.27) 57.03 (23.77) 43.85 (18.75) 44.5 (19.2) 48.23 (17.5) 48.84 (15.83) 46.6 (19.43) 44.5 (16.58)
AR LF/HF 2.54 (2.3) 1.22 (1.13) 1.67 (1.3) 1.88 (1.05) 1.91 (1.2) 1.48 (1.07) 1.63 (0.93) 1.83 (1.1)
p < 0.05, Post injection Group A vs Group A, first part of the study.
p < 0.05, Post injection Group B vs Group B, first part of the study.
p < 0.05, Post injection Group B vs Post injection Group A, first part of the study.
p < 0.05, Post injection Group A vs Group A, after cross-over procedure.
p < 0.05, Post injection Group B vs Group B, after cross-over procedure.
p < 0.05, Post injection Group B vs Post injection Group A, after cross-over procedure.
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decision with high doses of BoNT-A in stroke survivors affected by
cardiovascular comorbidities, inwhich a reduction in HRV is known
to be able to increase the incidence of cardiovascular events (Task
Force, 1996). Moreover, even in patients without known cardiac
diseases, our results can limit the potential concerns about the use
of BoNT-A at a dosage greater than 600 units.
As underlined, only few studies in literature investigated the
possible autonomic cardiovascular modifications induced by ona-
botulinumtoxinA, and with doses far lower than those utilised in
our work. Lastly, the fact that these two drugs at the same dose in
the same patients at different times induce the same modificationson HRV can in part explain the clinical results regarding efficacy and
safety found by Dressler (2009). However, due to the low sample
size, our data should be taken cautiously and for this reason further
experience with high dose use of BoNT-A is needed.
As a last consideration, our data suggest also, in line with the
results obtained by Dressler, that the treatment with high doses of
BoNT-A (both onabotulinumtoxinA and incobotulinumtoxinA) does
not seem to produce any cumulative effect on HRV modifications
and adverse events occurrence. Even though the overall study
period involved only two BoNT-A injections, these data are
consistent with previous studies of safety in multiple spasticity
treatment performed with BoNT-A and give further elements about
Table 3
Results of non-linear variables of the two groups in the first part of the study and after the crossover procedure, before and after BoNT-A treatment. Lmean: Recurrence plot
analysis - mean line length; Lmax: Recurrence plot analysis - maximum line length; REC: Recurrence plot analysis - recurrence rate; DET: determinism of the time series;
ShanEn: Shannon entropy; ApEn: Appoximate Entropy; SampEn: Sample Entropy; DFAa1: Detrended fluctuation analysis - short-term fluctuations; DFAa2 Detrended fluc-
tuation analysis - long-term fluctuations; D2: Correlation dimension; SD1: standard deviation of the Poincare plot perpendicular to line of identity; SD2: standard deviation of


















Lmean (beats) 19.62 (10.13) 20.69 (11.26) 14.23 (4.8) 17.83 (6.42) 16.54 (9.42) 21.29 (12.45) 14.87 (8.45) 18.42 (10.48)
Lmax (beats) 180.2 (172.5) 243.1 (142.5) 210.3 (131.8) 237.5 (122.3) 226 (168.2) 218.3 (130.3) 238.36 (137.2) 215.44 (119.76)
REC (%) 38.58 (15.43) 48.17 (10.42) 42.94 (11.36) 44.55 (11.85) 36.1 (18.7) 42.34 (9.66) 43.75 (12.45) 41.15 (13.72)
DET (%) 103.2 (4.9) 98.85 (1.13) 98.77 (2.04) 99.08 (3.13) 144 (8.3) 84.5 (7.47) 106.48 (20.42) 101.38 (18.81)
ShanEn 3.43 (0.67) 3.5 (0.33) 3.4 (0.37) 3.53 (0.36) 3.56 (0.41) 3.3 (0.68) 3.41 (0.74) 3.23 (0.45)
ApEn 1.09 (0.32) 1.01 (0.37) 1.11 (0.19) 0.93 (0.31) 1.02 (0.27) 0.97 (0.19) 1.04 (0.21) 1.02 (0.3)
SampEn 1.84 (0.33) 1.63 (0.31) 1.3 (0.25) 0.99 (0.42) 1.7 (0.42) 1.42 (0.26) 1.34 (0.53) 1.59 (0.61)
DFA:a1 1.132 (0.41) 0.7 (0.38) 0.99 (0.25) 1.02 (0.28) 0.89 (0.33) 0.84 (0.22) 1.043 (0.46) 0.93 (0.29)
DFA:a2 0.933 (0.19) 0.89 (0.3) 0.95 (0.12) 0.98 (0.15) 0.96 (0.26) 0.91 (0.33) 0.94 (0.29) 0.95 (0.41)
D2 0.73 (0.28) 0.58 (0.31) 0.55 (0.1) 0.83 (0.28) 0.64 (0.18) 0.66 (0.27) 0.73 (0.15) 0.71 (0.38)
SD1 (ms) 15.74 (11.51) 29.13 (13.34) 18.43 (6.25) 29.38 (15.02) 17.7 (10.63) 19.32 (9.49) 19.12 (12.36) 18.12 (14.72)
SD2 (ms) 39.16 (18.32) 44.03 (18.47) 39.9 (5.2) 54.60 (29.24) 38.89 (20.71) 45.42 (23.52) 39.07 (25.13) 42.60 (30.26)
p < 0.05, Post injection Group A vs Group A, first part of the study.
p < 0.05, Post injection Group B vs Group B, first part of the study.
p < 0.05, Post injection Group B vs Post injection Group A, first part of the study.
p < 0.05, Post injection Group A vs Group A, after cross-over procedure.
p < 0.05, Post injection Group B vs Group B, after cross-over procedure.
p < 0.05, Post injection Group B vs Post injection Group A, after cross-over procedure.
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survivors (Santamato et al., 2013; Baricich et al., 2015).
This study has several limitations: the first is the low sample
size; the second is the overall study duration (1 year) that hinders
the possibility to evaluate long-term modifications induced by
multiple BoNT-A injections.
5. Conclusions
In conclusion, this study confirms the safety of incobotuli-
numtoxinA at doses up to 12 units/kg regarding the autonomic
heart drive modifications and adverse events occurrence in adult
stroke hemiplegic spastic patients. Moreover, for the first time in
literature, this study shows the same results in terms of safety of
onabotulinumtoxinA. Lastly, multiple administrations of BoNT-A at
high doses in adult hemiplegic patients do not seem to induce any
cumulative effect. However, further experience with high doses of
BoNT-A is needed in order to confirm these results and, in partic-
ular, for the clinical use of these two BoNT-A formulations in pa-
tients with cardiovascular comorbidities.
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